tirzepatide — 22 things I got wrong before I got it right
tirzepatide — 22 things I got wrong before I got it right. I have gone back and forth on this for months.
The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.
Sceptical readings welcome. The confident ones are the ones I distrust.
best — the order this archive was captured in
The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.
The distribution matters more than the mean.
Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.
Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.
Saving this one. It is the clearest statement of the stall problem I have read here.
Which week did the appetite change actually land for you?
Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.
Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.
Went 10 to 12.5 on the calendar and had the worst fortnight of the whole run. Dropped back to 10 and everything settled.
Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.
Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.
sulphur burps are the signature complaint and they are not dangerous
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
Trial identifiers corrected in the title. SURMOUNT and SURPASS are different programmes.
I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your fatigue pattern is a guess.
Came off sema and onto tirz with a two-week gap. The first month was flat and I assumed I had made a mistake. Month two it moved.
if 7.5 is working, 10 is not automatically better
switching from sema is not a dose conversion, there is no clean equivalence
I would separate the two claims.
tove_vasquez is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.
pens and vials are the same molecule, the price is the difference
- 1I would separate the two claims. That the GIP arm exists is uncontroversial;…6 comments in this branch · started by u/tove_vasquez